Apellis Pharmaceuticals Investor Presentation — December 2021

Abstract #2194Post Hoc Analysis of the Effect of Pegcetacoplan Treatment of Patients with Paroxysmal Nocturnal Hemoglobinuria and Baseline Hemoglobin Levels Greater Than 10 Grams per Deciliter 1Department of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, Univ